Montreal – October 7, 2021 – CQDM, the Canadian Cancer Society (CCS), the Cole Foundation (CF) and Oncopole – Pôle cancer du FRQS launch a first call for proposals to support collaborative R&D projects focusing on pediatric and young adult cancers, in particular leukemia and lymphoma. This new research funding, worth up to $5M, builds on CCS, CF, Oncopole and CQDM strong commitment to accelerate the development of platforms, tools and products necessary to support advances in pediatric and young patient cancer prevention, diagnosis and treatment.
Through this new partnership, Quebec academic researchers conducting translational pediatric oncology research could be awarded grants representing up to 90% of their project value (for projects with a $2M maximum value). At least 1 biotechnology or pharmaceutical firm having R&D and/or production activities in Quebec must partner up with the research team and commit to provide a 10% minimum contribution. Projects that meet the “SynergiQC-Pediatric oncology” eligibility requirements will be considered.
Quebec academic researchers interested in this opportunity are invited to submit their application no later than December 8th, 2021. Please visit “SynergiQC-Pediatric oncology” for all the details on this initiative.
For more information or questions, contact Véronique Dugas, Vice-President, Scientific Affairs at CQDM.
“We are pleased to be collaborating with CQDM, the Cole Foundation and Oncopole on this project. Childhood cancer is the number one cause of disease-related death in Canadian children under the age of 15, and 2 out of 3 childhood cancer survivors suffer long-term side effects from their treatment. This funding will accelerate the development of innovative products required to support Quebec’s youngest cancer patients”, said Andrea Seale, CEO, Canadian Cancer Society.
“Partnerships allow for more research projects to be funded than each organization could support based upon their own limited financial resources. We celebrate this collaboration by these senior organizations working together for the common goal of combating pediatric/young adult cancers”, said Barry Cole President and Chair of the Cole Foundation.
“Collaborative research is key to accelerate the development of innovative and competitive products and technologies. This new partnership with the Canadian Cancer Society, the Cole Foundation and the Fonds de Recherche du Québec en Santé therefore makes it possible to address crucial needs specific to pediatric oncology and support the most promising projects”, said Diane Gosselin, CEO at CQDM.
“This major collaborative investment makes it possible to combine the efforts of researchers, companies and funding organizations to set up projects with significant outcomes, primarily for young cancer patients but also for Quebec as a whole. We are pleased to join leading partners such as CQDM, the Canadian Cancer Society and the Cole Foundation in this initiative” said Carole Jabet, director of the Oncopole.
About the Canadian Cancer Society
The Canadian Cancer Society works tirelessly to save and improve lives. We fund the brightest minds in cancer research. We provide a compassionate support system for all those affected by cancer, from coast to coast and for all types of cancer. As the voice for Canadians who care about cancer, we work with governments to establish health policies to prevent cancer and better support those living with the disease. No other organization does all that we do to improve lives today and to change the future of cancer forever. Help us make a difference. Call 1-888-939-3333 or visit cancer.ca today.
About the Cole Foundation
The Cole Foundation was created in 1980 as a private initiative in Montreal to promote research and patient care in the area of pediatric and young adult leukemia and lymphoma. The initiative aims to break down barriers, encourage closer collaborations between institutions, develop new research teams and promote new ideas to impact cancer. Website: colefoundation.ca
About CQDM
CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs. We bring together world-class pharmaceutical corporations, several Canadian biotech companies, the best scientists from both the public and private sectors, as well as the Canadian and Québec governments. CQDM’s collaborative approach bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. For more information – Website: cqdm.org, LinkedIn and Twitter.
About the Oncopole
Oncopole, pôle cancer du FRQS, a Quebec hub for research, development and investment to accelerate the fight against cancer, is the product of a unique co-creation process made possible thanks to our founding partner Merck Canada. Oncopole’s mission is to act as a catalyst leveraging actions made by the key players in Quebec’s oncology and innovation research ecosystem. As a result, it aims to position the province as a leader in the field. For more information, go to: oncopole.ca
Contact
CQDM
Véronique Dugas
Vice-President – Scientific Affairs, CQDM
vdugas@cqdm.org
